Outlook Therapeutics (OTLK) Long-Term Debt Issuances: 2015-2017
Historic Long-Term Debt Issuances for Outlook Therapeutics (OTLK) over the last 1 years, with Jun 2017 value amounting to $5.0 million.
- Outlook Therapeutics' Long-Term Debt Issuances rose 3067584.66% to $5.0 million in Q2 2017 from the same period last year, while for Jun 2017 it was $15.0 million, marking a year-over-year increase of 358.19%. This contributed to the annual value of $30.0 million for FY2023, which is 200.00% up from last year.
- According to the latest figures from Q2 2017, Outlook Therapeutics' Long-Term Debt Issuances is $5.0 million, which was up 203.03% from $1.6 million recorded in Q1 2017.
- Outlook Therapeutics' 5-year Long-Term Debt Issuances high stood at $8.3 million for Q4 2016, and its period low was -$163 during Q2 2016.
- In the last 3 years, Outlook Therapeutics' Long-Term Debt Issuances had a median value of $1.1 million in 2016 and averaged $2.3 million.
- In the last 5 years, Outlook Therapeutics' Long-Term Debt Issuances crashed by 100.01% in 2016 and then spiked by 3,067,584.66% in 2017.
- Over the past 3 years, Outlook Therapeutics' Long-Term Debt Issuances (Quarterly) stood at $187,388 in 2015, then soared by 4,356.00% to $8.3 million in 2016, then skyrocketed by 3,067,584.66% to $5.0 million in 2017.
- Its Long-Term Debt Issuances was $5.0 million in Q2 2017, compared to $1.6 million in Q1 2017 and $8.3 million in Q4 2016.